| Literature DB >> 16085310 |
Michèle Masquelier1, Bo Lundberg, Curt Peterson, Sigurd Vitols.
Abstract
The use of low density lipoprotein (LDL) as drug carrier in acute myeloblastic leukemia chemotherapy is attractive due to high LDL uptake by leukemic cells. Lipid-based formulations, such as liposomes or microemulsions are promising alternatives. In the current study, we incorporated N-trifluoroacetyl-adriamycin-14-valerate (AD32), a lipophilic derivative of daunorubicin (DNR), and WB4291, a lipophilic alkylating agent, into LDL or lipid microemulsions and evaluated their cytotoxic activities towards leukemic cell lines using as references DNR and melphalan. The incorporation of AD32 into LDL or emulsion resulted in complexes with poor cytotoxicity. WB4291-LDL and WB4291-emulsion exerted, on the other hand, promising cytotoxic effects towards parental and resistant K562 and HL60 cell lines.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16085310 DOI: 10.1016/j.leukres.2005.06.012
Source DB: PubMed Journal: Leuk Res ISSN: 0145-2126 Impact factor: 3.156